Indeed, lacking ER, PR and HER2 expression, patients affected by this kind of tumor do not benefit of the therapeutic regimens (i.e. endocrine and target therapies) effective against other BC subtypes [2]. This evidence concerns the gene ERBB2 and neoplasm.